Addition Of Everolimus To Exemestine Provides Sustained Survival Edge In ... Medical News Today SAN ANTONIO - The survival benefit seen with everolimus plus exemestane over exemestane alone at 7.5 months and 12.5 months in women with advanced breast cancer is maintained at 18- month follow-up, investigators announced at the San Antonio ... |
